Attention Medical Professionals: PJSC Kraspharma has registered a new medicinal product — a 4th-generation fluoroquinolone: Moxifloxacin IV infusion solution, 1.6 mg/ml.
01.04.2018
Attention Medical Professionals: PJSC Kraspharma has registered a new medicinal product — a 4th-generation fluoroquinolone: Moxifloxacin IV infusion solution, 1.6 mg/ml.
PJSC "Kraspharma" Expands Its Product Portfolio: New Antimicrobial Agent Moxifloxacin (1.6 mg/ml, Infusion Solution) Registered
PJSC Kraspharma has expanded its product line with the registration of a new antimicrobial agent from the fluoroquinolone group — Moxifloxacin, available in the dosage form “infusion solution” at a concentration of 1.6 mg/ml.
Moxifloxacin is a 4th-generation fluoroquinolone with a broad spectrum of activity that includes key Gram-positive and Gram-negative bacteria, anaerobes, atypical pathogens, and mycobacteria. A notable feature of Moxifloxacin’s antimicrobial profile is its effectiveness against microorganisms resistant to cephalosporins and macrolides.
The drug is indicated for a wide range of infections, particularly:
Lower respiratory tract infections,
Intra-abdominal infections, and
Complicated skin and soft tissue infections.
In cases of mixed aerobic-anaerobic infections, Moxifloxacin monotherapy eliminates the need for combination with additional anti-anaerobic agents.
The therapy is generally well tolerated, and the drug is characterized by a high safety profile.
A detailed description of Moxifloxacin is available via the following link >>
PJSC Kraspharma has expanded its product line with the registration of a new antimicrobial agent from the fluoroquinolone group — Moxifloxacin, available in the dosage form “infusion solution” at a concentration of 1.6 mg/ml.
Moxifloxacin is a 4th-generation fluoroquinolone with a broad spectrum of activity that includes key Gram-positive and Gram-negative bacteria, anaerobes, atypical pathogens, and mycobacteria. A notable feature of Moxifloxacin’s antimicrobial profile is its effectiveness against microorganisms resistant to cephalosporins and macrolides.
The drug is indicated for a wide range of infections, particularly:
Lower respiratory tract infections,
Intra-abdominal infections, and
Complicated skin and soft tissue infections.
In cases of mixed aerobic-anaerobic infections, Moxifloxacin monotherapy eliminates the need for combination with additional anti-anaerobic agents.
The therapy is generally well tolerated, and the drug is characterized by a high safety profile.
A detailed description of Moxifloxacin is available via the following link >>
